Starling Oncology, Inc.

STLN Healthcare Medical Care Facilities

Starling Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.7 million, up 27.8% from fiscal 2024. In the quarter to June 2026, revenue grew 34.6%, EPS grew 46.7%, free cash flow grew 196.7% and total debt rose 6.46%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

6.43 0.48 −6.95%
Market cap
$690.9M
P/E
0.0×
Fwd P/E
−32.5×
Dividend yield
—
F-score
4/9
Altman Z
1.42
Beneish M
−3.39
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
5 4 4 4

+8 more TTM periods

ROE
214.12% 775.91% 999.19% (4,132.17%)
ROA
(21.47%) (26.19%) (35.93%) (38.67%)
ROIC
(117.66%) (63.75%) (80.21%) (70.85%)
Return on Tangible Assets
(81.31%) (90.26%) (115.51%) (120.02%)
Average Days of Receivables
41.46 39.76 43.07 47.48
Free Cash Flow per Share
(0.03) (0.25) (0.30) (0.28)
Free Cash Flow
(3.29) (25.73) (27.79) (27.53)
Other line items

Show all line items

Columns are period end dates